Article Text

Download PDFPDF

Oxytetracycline in the treatment of ocular rosacea: a double-blind trial.
  1. R S Bartholomew,
  2. B J Reid,
  3. M J Cheesbrough,
  4. M Macdonald and
  5. N R Galloway


    Thirty-five patients with ocular rosacea were admitted to a trial of systemic oxytetracycline, 250 mg b.d. for 6 weeks. Oxytetracycline produced a significantly higher number of remissions than the placebo, 11/35. With repeated or continuous treatment 19/35 patients achieved a sustained remission for 8 months. There were no side effects. The nonspecific signs of ocular rosacea responded well to the treatment, but no permanent change in the conjunctival or corneal vascularisation occurred.

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.